IL23R genotyping suggests disease-modifying effects of rs11209026 (p.Arg381Gln) and rs7530511 (p.Leu310Pro) in patients requiring ustekinumab. Conclusions New onset psoriasiform skin lesions develop ...

The researchers focused specifically on the IL23R gene, which plays a key role in immune regulation. "The exact causes of chronic inflammatory bowel diseases remain unknown. However, previous ...

an investigational oral peptide IL23R inhibitor that is in preclinical development for the treatment of psoriasis. According to the company, Nimble's platform for peptide synthesis, screening, and ...

Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble's peptide synthesis, screening, and ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

The acquisition includes Nimble's investigational lead candidate, an oral peptide IL23R inhibitor currently in preclinical development for psoriasis, and a pipeline of new oral peptide candidates ...

The acquisition includes Nimble’s investigational lead candidate, an oral peptide IL23R inhibitor currently in preclinical development for psoriasis, and a pipeline of new oral peptide candidates ...

AbbVie has agreed to acquire Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis, and a pipeline of ...

NORTH CHICAGO, IL and MADISON, WI, USA I December 13, 2024 I AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its ...

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...